TETERBORO, N.J., Oct 25, 2004 /PRNewswire-FirstCall via COMTEX/ -- Quest Diagnostics
Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing,
information and services, announced that for the third quarter ended September
30, 2004, net income increased to $130 million, or $1.26 per diluted share,
compared to $120 million, or $1.12 per diluted share, in 2003.
Third quarter revenues grew 5.6% over the prior-year level to $1.3
billion. Clinical testing volume, measured by the number of requisitions,
increased 3.3%, and revenue per requisition increased 1.9%. The remainder of
the revenue growth was contributed by the company's non-clinical testing
businesses.
During the quarter, the estimated impact of hurricanes on the company's
business in the southeastern U.S. reduced revenue growth by slightly more than
half a percentage point and reduced earnings per share by $0.03.
For the third quarter, operating income was $232 million, or 18% of
revenues, compared to $218 million, or 17.8% of revenues, in 2003. Bad debt
expense was 4.6% of revenues, compared to 4.8% a year ago. Days sales
outstanding were 48 days, unchanged from a year ago. Cash from operations
increased to $217 million from $173 million in 2003. During the quarter the
company repurchased $110 million of its common stock and made capital
expenditures of $43 million.
"We delivered strong financial performance in the third quarter," said
Surya N. Mohapatra, Ph.D., President and Chief Executive Officer. "Quest
Diagnostics continues to differentiate itself successfully in the marketplace
by providing patients and physicians with innovative science and medicine,
advanced information technology, unparalleled access and distribution, and the
benefits of our long-standing commitment to Six Sigma quality, enabling us to
drive improvements in revenues, earnings per share and cash generation."
For the first nine months of 2004, excluding special charges in the second
quarter related to the CEO succession process and the company's debt
refinancing, net income increased to $381 million, and earnings per diluted
share increased 17% to $3.64 from $3.10 in 2003. Including the second quarter
charges, net income was $373 million and earnings per diluted share were
$3.56. Revenues increased 8.8% to $3.8 billion. Operating income, excluding
the charge for the CEO succession process, was $681 million, or 17.7% of
revenues, compared to $599 million, or 17% of revenues in 2003. Including the
charge, operating income was $671 million, or 17.4% of revenues. Through the
first nine months of 2004, the company repurchased $381 million of its common
stock and made capital expenditures of $134 million.
Outlook for Fourth Quarter and Full-Year 2004
For the fourth quarter, revenues are expected to grow approximately 6%,
operating income is expected to be between 17% and 18% of revenues, and
earnings per diluted share are expected to be between $1.18 and $1.23 before a
required change in the accounting for the company's contingent convertible
debentures. Including the change in accounting, earnings per diluted share
are expected to be between $1.15 and $1.20.
For the full year 2004, revenues are expected to grow approximately 8%,
with growth of about 1.5% contributed by Unilab, acquired February 28, 2003.
Operating income is expected to approach 18% of revenues, cash from operations
is expected to exceed $700 million, and capital expenditures are expected to
be between $180 million and $190 million.
The company expects full year earnings per diluted share of between $4.82
and $4.87, before the second quarter special charges and the change in
accounting for the company's contingent convertible debentures. Including
these items, earnings per diluted share are expected to be between $4.64 and
$4.69.
Quest Diagnostics will hold its third quarter conference call on October
25 at 8:30 A.M. Eastern Time. To hear a simulcast of the call over the
Internet or a replay, registered analysts may access StreetEvents at:
http://www.streetevents.com, and all others may access the Quest Diagnostics
website at: http://www.questdiagnostics.com. In addition, a replay of the call
will be available from 10:30 A.M. on October 25 through 11 P.M. on November 26
to investors in the U.S. by dialing 866-407-9273. Investors outside the U.S.
may dial 203-369-0618. No password is required for either number.
Quest Diagnostics Incorporated is the nation's leading provider of
diagnostic testing, information and services, providing insights that enable
healthcare professionals to make decisions that improve health. The company
offers the broadest access to diagnostic testing services through its national
network of laboratories and patient service centers, and provides interpretive
consultation through its extensive medical and scientific staff. Quest
Diagnostics is the leading provider of esoteric testing, including gene-based
medical testing, and provides advanced information technology solutions to
improve patient care. Additional company information is available at:
http://www.questdiagnostics.com.
The statements in this press release which are not historical facts or
information may be forward-looking statements. These forward-looking
statements involve risks and uncertainties that could cause actual results and
outcomes to be materially different. Certain of these risks and uncertainties
may include, but are not limited to, competitive environment, changes in
government regulations, changing relationships with customers, payers,
suppliers and strategic partners and other factors described in the Quest
Diagnostics Incorporated 2003 Form 10-K and subsequent filings.
Quest Diagnostics Incorporated and Subsidiaries
Consolidated Statements of Operations
For the Three and Nine Months Ended September 30, 2004 and 2003
(in millions, except per share data)
Three Months Ended Nine Months Ended
September 30, September 30,
2004 2003 2004 2003
Net revenues $1,289.9 $1,221.2 $3,843.3 $3,534.0
Operating costs and
expenses:
Cost of services 748.4 711.2 2,233.3 2,062.4
Selling, general and
administrative 308.3 292.4 923.2 867.7
Amortization of
intangible assets 1.7 2.0 5.8 6.1
Other operating
(income) expense, net (0.2) (1.9) 10.4 (1.7)
Total operating
costs and expenses 1,058.2 1,003.7 3,172.7 2,934.5
Operating income 231.7 217.5 670.6 599.5
Other income (expense):
Interest expense, net (13.6) (14.5) (44.6) (45.2)
Minority share of income (4.9) (4.6) (14.4) (12.8)
Equity earnings in
unconsolidated joint
ventures 5.5 4.4 15.5 13.0
Other income (expense),
net -- (0.1) -- 0.5
Total non-operating
expenses, net (13.0) (14.8) (43.5) (44.5)
Income before taxes 218.7 202.7 627.1 555.0
Income tax expense 88.6 82.7 254.0 226.5
Net income $130.1 $120.0 $373.1 $328.5
Net income before
special charges $130.1 $120.0 $381.0 $328.5
Basic earnings per
common share:
Net income $1.29 $1.15 $3.64 $3.18
Net income before
special charges $1.29 $1.15 $3.72 $3.18
Weighted average
common shares
outstanding - basic 101.2 104.8 102.5 103.3
Diluted earnings per common share:
Net income $1.26 $1.12 $3.56 $3.10
Net income before
special charges $1.26 $1.12 $3.64 $3.10
Weighted average
common shares
outstanding - diluted 103.3 107.3 104.8 105.8
Operating income before
special charge as a
percentage of net
revenues 18.0% 17.8% 17.7% 17.0%
Quest Diagnostics Incorporated and Subsidiaries
Consolidated Balance Sheets
September 30, 2004 and December 31, 2003
(in millions, except per share data)
September 30, December 31,
2004 2003
Assets
Current assets:
Cash and cash equivalents $201.0 $155.0
Accounts receivable, net 686.0 609.2
Inventories 73.2 72.5
Deferred income taxes 98.3 109.0
Prepaid expenses and other current assets 54.3 50.1
Total current assets 1,112.8 995.8
Property, plant and equipment, net 618.0 607.3
Goodwill, net 2,517.3 2,518.9
Intangible assets, net 12.4 17.0
Deferred income taxes 33.0 49.6
Other assets 101.5 112.8
Total assets $4,395.0 $4,301.4
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued expenses $649.7 $649.9
Short-term borrowings and current
portion of long-term debt 130.2 73.9
Total current liabilities 779.9 723.8
Long-term debt 971.8 1,028.7
Other liabilities 165.6 154.2
Common stockholders' equity:
Common stock, par value $0.01 per share;
300 shares authorized; 106.8 shares
issued at both September 30, 2004
and December 31, 2003 1.1 1.1
Additional paid-in capital 2,214.3 2,267.0
Retained earnings 707.6 380.5
Unearned compensation (0.2) (2.3)
Accumulated other comprehensive income 0.2 5.9
Treasury stock, at cost; 5.8 and 4.0
shares at September 30, 2004 and
December 31, 2003, respectively (445.3) (257.5)
Total common stockholders' equity 2,477.7 2,394.7
Total liabilities and stockholders' equity $4,395.0 $4,301.4
Quest Diagnostics Incorporated and Subsidiaries
Consolidated Statements of Cash Flows
For the Nine Months Ended September 30, 2004 and 2003
(in millions)
Nine Months Ended
September 30,
2004 2003
Cash flows from operating activities:
Net income $373.1 $328.5
Adjustments to reconcile net income
to net cash provided by operating
activities:
Depreciation and amortization 126.4 113.5
Provision for doubtful accounts 172.0 172.1
Deferred income tax provision 31.4 16.6
Minority share of income 14.4 12.8
Stock compensation expense 1.2 4.1
Tax benefits associated with stock-based
compensation plans 54.2 17.9
Other, net 2.5 (1.8)
Changes in operating assets and liabilities:
Accounts receivable (248.9) (232.0)
Accounts payable and accrued expenses (10.3) (67.4)
Integration, settlement and other
special charges (17.4) (13.8)
Income taxes payable 27.2 43.7
Other assets and liabilities, net 9.4 6.3
Net cash provided by operating activities 535.2 400.5
Cash flows from investing activities:
Business acquisitions, net of cash acquired -- (237.5)
Capital expenditures (134.1) (121.7)
Proceeds from disposition of assets 7.5 9.0
Increase in investments and other assets (3.2) (11.4)
Net cash used in investing activities (129.8) (361.6)
Cash flows from financing activities:
Proceeds from borrowings 304.9 450.0
Repayments of debt (305.9) (372.8)
Purchases of treasury stock (381.2) (124.1)
Exercise of stock options 83.1 16.8
Dividends paid (46.2) --
Distributions to minority partners (12.0) (10.6)
Financing costs paid (2.1) (4.2)
Other -- 0.3
Net cash used in financing activities (359.4) (44.6)
Net change in cash and cash equivalents 46.0 (5.7)
Cash and cash equivalents, beginning of period 155.0 96.8
Cash and cash equivalents, end of period $201.0 $91.1
Cash paid during the period for:
Interest $47.4 $55.0
Income taxes $143.3 $150.3
Non-cash financing activities:
Treasury stock purchases not settled $ -- $ 17.3
Notes to Financial Tables
1) Net income per common share is computed by dividing net income by the
weighted average number of common shares outstanding.
Potentially dilutive common shares primarily represent stock options.
The following table presents net income and basic and diluted earnings
per common share, had the Company elected to recognize compensation
cost based on the fair value at the grant dates for stock option awards
and discounts granted for stock purchases under the Company's Employee
Stock Purchase Plan, consistent with the method prescribed by Statement
of Financial Accounting Standards No. 123, "Accounting for Stock-Based
Compensation", as amended by Statement of Financial Accounting
Standards No. 148, "Accounting for Stock-Based Compensation -
Transition and Disclosure - an amendment of FASB Statement No. 123":
Three Months Ended Nine Months Ended
September 30, September 30,
2004 2003 2004 2003
(in millions, except per share data)
Net income
Net income, as reported $130.1 $120.0 $373.1 $328.5
Add: Stock-based compensation
under APB 25 0.2 1.2 1.2 4.1
Deduct: Total stock-based
compensation expense determined
under fair value method for all
awards, net of related tax
effects (11.7) (12.2) (33.5) (40.2)
Pro forma net income $118.6 $109.0 $340.8 $292.4
Earnings per common share
Basic - as reported $1.29 $1.15 $3.64 $3.18
Basic - pro forma $1.17 $1.04 $3.33 $2.83
Diluted - as reported $1.26 $1.12 $3.56 $3.10
Diluted - pro forma $1.15 $1.03 $3.27 $2.80
The fair value of each option grant was estimated on the date of grant
using the Black-Scholes option-pricing model with the following weighted
average assumptions:
Three Months Ended Nine Months Ended
September 30, September 30,
2004 2003 2004 2003
Dividend yield 0.7% 0.0% 0.7% 0.0%
Risk-free interest rate 3.7% 3.3% 3.1% 2.8%
Expected volatility 46.6% 48.1% 47.2% 48.1%
Expected holding period, in years 5 5 5 5
2) Other operating expense, net represents miscellaneous income and
expense items related to operating activities including gains and
losses associated with the disposal of operating assets. For the nine
months ended September 30, 2004, other operating expense, net includes
a $10.3 million charge associated with the acceleration of certain
pension obligations in connection with the CEO succession process.
3) Interest expense, net for the nine months ended September 30, 2004,
includes a $2.9 million charge representing the write-off of deferred
financing costs associated with the second quarter 2004 refinancing of
the Company's bank debt and credit facility.
4) In 2003, the Board of Directors authorized a share repurchase program,
which permits the Company to purchase up to $600 million of its common
stock. In July 2004, the Board of Directors authorized the Company to
purchase up to an additional $300 million of its common stock. For the
three months ended September 30, 2004, the Company repurchased
approximately 1.3 million shares of its common stock at an average
price of $81.64 per share for a total of $110 million. For the nine
months ended September 30, 2004, the Company repurchased approximately
4.5 million shares of its common stock at an average price of $83.84
per share for a total of $381 million. Since the inception of the
share repurchase program, the Company has repurchased approximately 8.5
million shares of its common stock at an average price of $74.82 for a
total of $639 million. For the nine months ended September 30, 2004,
the Company has reissued approximately 2.8 million of these shares in
connection with employee benefit plans. At September 30, 2004, $261
million of the share repurchase authorization remained available.
5) Free cash flow represents net cash provided by operating activities
less capital expenditures. Free cash flow is presented because
management believes it is a useful adjunct to cash flow from operating
activities and other measurements under accounting principles generally
accepted in the United States since it is a meaningful measure of a
company's ability to fund investing activities and meet its future debt
service requirements. Free cash flow is not a measure of financial
performance under accounting principles generally accepted in the
United States and should not be considered as an alternative to cash
flows from operating, investing or financing activities as an indicator
of cash flows or as a measure of liquidity. The following table
reconciles net cash provided by operating activities to free cash flow:
Nine Months Ended
September 30,
2004 2003
(in millions)
Net cash provided by operating activities $535.2 $400.5
Less: Capital expenditures 134.1 121.7
Free cash flow $401.1 $278.8
6) Net income before special charges excludes the charges associated with
the acceleration of certain pension obligations in connection with the
CEO succession process and the second quarter 2004 refinancing of the
Company's bank debt and credit facility. Operating income before
special charge excludes the charge associated with the CEO succession
process. Both operating income and net income before special charges,
including per common share amounts, are presented because management
believes that it is a useful adjunct to other measurements under
accounting principles generally accepted in the United States,
including reported operating income and net income since it is a
meaningful measure of the Company's on-going operating performance and
is on a basis consistent with prior reported results. Operating income
before special charge and net income before special charges, including
per common share amounts, are not measures of financial performance
under accounting principles generally accepted in the United States and
should not be considered as an alternative to reported operating income
and net income as an indicator of performance. The following table
reconciles operating income and net income before special charges to
reported results:
For the Nine Months Ended September 30, 2004
(in millions, except per share amounts)
Special Charges Related to:
Acceleration
Before of Certain
Special Pension Debt
Charges Obligations Refinancing As Reported
Net revenues $3,843.3 $-- $-- $3,843.3
Operating income $680.9 $(10.3) $-- $670.6
Interest expense, net (41.7) -- (2.9) (44.6)
Income before taxes $640.3 $(10.3) $(2.9) $627.1
Income tax expense
(benefit) 259.3 (4.1) (1.2) 254.0
Net income $381.0 $(6.2) $(1.7) $373.1
Basic earnings per
common share:
Net income $3.72 $(0.06) $(0.02) $3.64
Diluted earnings per
common share:
Net income $3.64 $(0.06) $(0.02) $3.56
Operating income as a
percentage of net
revenues (A) 17.7% 17.4%
(A) Calculated by dividing operating income by net revenues
7) Estimated comparable diluted earnings per common share represents
management's estimate of diluted earnings per common share before
charges associated with the acceleration of certain pension obligations
in connection with the CEO succession process, the second quarter
refinancing of the Company's bank debt and credit facility, and the
required change in accounting for the Company's contingent convertible
debentures. Estimated comparable diluted earnings per common share is
presented because management believes it is a useful adjunct to
estimated diluted earnings per common share and other measurements
under accounting principles generally accepted in the United States
since it is a meaningful measure of the Company's ongoing operating
performance and is on a basis consistent with previous estimates of
diluted earnings per common share. Estimated comparable diluted
earnings per common share is not a measure of financial performance
under accounting principles generally accepted in the United States and
should not be considered as an alternative to estimated diluted
earnings per common share. The following table reconciles estimated
diluted earnings per common share to estimated comparable diluted
earnings per common share:
Three Months Ended Twelve Months Ended
December 31, 2004 December 31, 2004
Estimated diluted earnings
per common share $1.15 - $1.20 $4.64 - $4.69
Add:
Charge related to the
acceleration of certain
pension obligations 0.00 0.06
Refinancing charge 0.00 0.02
Estimated impact of change
in accounting for contingent
convertible debentures 0.03 0.10
Estimated comparable diluted
earnings per common share $1.18 - $1.23 $4.82 - $4.87
SOURCE Quest Diagnostics Incorporated
Laure Park, Investors, +1-201-393-5030, and Gary Samuels,
Media, +1-201-393-5700, both of Quest Diagnostics Incorporated
http://www.questdiagnostics.com